Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization

Tong Ye, Zhouguang Jiao, Xin Li, Zhanlong He, Yanyan Li, Fengmei Yang, Xin Zhao, Youchun Wang, Weijin Huang, Meng Qin, Yingmei Feng, Yefeng Qiu, Wenhui Yang, Lingfei Hu, Yaling Hu, Yu Zhai, Erqiang Wang, Di Yu, Shuang Wang, Hua Yue, Yishu Wang, Hengliang Wang (), Li Zhu (), Guanghui Ma () and Wei Wei ()
Additional contact information
Tong Ye: Chinese Academy of Sciences
Zhouguang Jiao: Chinese Academy of Sciences
Xin Li: Chinese Academy of Sciences
Zhanlong He: Chinese Academy of Medical Sciences
Yanyan Li: Chinese Academy of Medical Sciences
Fengmei Yang: Chinese Academy of Medical Sciences
Xin Zhao: Chinese Academy of Medical Sciences
Youchun Wang: National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals
Weijin Huang: National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals
Meng Qin: Beijing University of Chemical Technology
Yingmei Feng: Capital Medical University
Yefeng Qiu: Academy of Military Medical Science
Wenhui Yang: Beijing Institute of Microbiology and Epidemiology
Lingfei Hu: Beijing Institute of Microbiology and Epidemiology
Yaling Hu: Sinovac Life Sciences Co., Ltd.
Yu Zhai: Sinovac Life Sciences Co., Ltd.
Erqiang Wang: Sinovac Life Sciences Co., Ltd.
Di Yu: The University of Queensland
Shuang Wang: Chinese Academy of Sciences
Hua Yue: Chinese Academy of Sciences
Yishu Wang: Chinese Academy of Sciences
Hengliang Wang: Beijing Institute of Biotechnology
Li Zhu: Beijing Institute of Biotechnology
Guanghui Ma: Chinese Academy of Sciences
Wei Wei: Chinese Academy of Sciences

Nature, 2023, vol. 624, issue 7992, 630-638

Abstract: Abstract The COVID-19 pandemic has fostered major advances in vaccination technologies1–4; however, there are urgent needs for vaccines that induce mucosal immune responses and for single-dose, non-invasive administration4–6. Here we develop an inhalable, single-dose, dry powder aerosol SARS-CoV-2 vaccine that induces potent systemic and mucosal immune responses. The vaccine encapsulates assembled nanoparticles comprising proteinaceous cholera toxin B subunits displaying the SARS-CoV-2 RBD antigen within microcapsules of optimal aerodynamic size, and this unique nano–micro coupled structure supports efficient alveoli delivery, sustained antigen release and antigen-presenting cell uptake, which are favourable features for the induction of immune responses. Moreover, this vaccine induces strong production of IgG and IgA, as well as a local T cell response, collectively conferring effective protection against SARS-CoV-2 in mice, hamsters and nonhuman primates. Finally, we also demonstrate a mosaic iteration of the vaccine that co-displays ancestral and Omicron antigens, extending the breadth of antibody response against co-circulating strains and transmission of the Omicron variant. These findings support the use of this inhaled vaccine as a promising multivalent platform for fighting COVID-19 and other respiratory infectious diseases.

Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-023-06809-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:624:y:2023:i:7992:d:10.1038_s41586-023-06809-8

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-023-06809-8

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().